Predicting Radio Sensitivity in Bladder Cancer
Author Information
Author(s): Abdel Raheem Ahmad M, Hameed Diaa A, ElGanainy Ehab O, Mosad Eman, Abdelwanis Mostafa E, Kamel Nermen A, Hammouda Hisham M, Abdelaziz Mohammad A, Hemeyda Khaled
Primary Institution: Assiut University Hospital, Assiut, Egypt
Hypothesis
Can Bcl-XL expression predict the radio sensitivity of Bilharzial-related squamous bladder carcinoma?
Conclusion
Adjuvant radiotherapy for muscle invasive bilharzial related squamous cell carcinoma of the urinary bladder has potential effectiveness and minor side effects.
Supporting Evidence
- The disease free cumulative survival was 48% for patients receiving adjuvant radiotherapy.
- Positive Bcl-XL expression was associated with a higher recurrence rate.
- Adjuvant radiotherapy showed a mean disease free survival of 26 months compared to 18 months without it.
Takeaway
This study looked at how a protein called Bcl-XL can help doctors know if a treatment for bladder cancer will work. It found that some patients might not benefit from the treatment.
Methodology
The study included 71 patients with muscle invasive bilharzial related squamous cell carcinoma who underwent radical cystectomy, with some receiving adjuvant radiotherapy and others not.
Potential Biases
Potential bias due to non-randomized patient selection based on personal and cultural preferences.
Limitations
The study was not a formal randomization of treatment groups due to patient choice influenced by cultural and socioeconomic factors.
Participant Demographics
47 males and 24 females, aged <50 and ≥50.
Statistical Information
P-Value
< 0.0001
Confidence Interval
95% CI 8.4 - 102.3
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website